Skip to content

A study on Efficacy of individualized Homoeopathic medicines vs conventional medicine in treatment of Chronic Migraine

A randomised comparative study to evaluate the efficacy of individualized Homoeopathic medicines vs conventional medicine in treatment of Chronic Migraine - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/064972
Enrollment
60
Registered
2024-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G437- Chronic migraine without aura Health Condition 2: G431- Migraine with aura Health Condition 3: G430- Migraine without aura

Interventions

Intervention1: Homoeopathic medicine: Homoeopathic medicine will be given in Centesimal or LM potency. Dose and potency will be given as per the need of the case. Route of administration is oral. Tota

Sponsors

CCRH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of age group between 15- 50 years. 2.Patients of both genders and all religion. 3.Patients willing to provide written informed consent. 4.Patients who is willing to complete all the scheduled study visits. 5.Patient falling in Grade I and II of MIDAS score. 6.Patients having chronic migraine fulfilling the criteria of ICHD-3 for Chronic migraine(The International Classification of Headache Disorders 3rd edition).

Exclusion criteria

Exclusion criteria: 1.Any headache other than migraine (i.e. those not meeting ICHD-3 criteria). 2.Patients unwilling to participate in the study. 3.Patient who are pregnant or lactating mother. 4.Patients with other co-morbidities such as uncontrolled diabetes and/or hypertension, thyroid disorders, autoimmune diseases, end stage kidney disease or end stage liver disease or any malignancy etc. 5.Patient undergoing any form of treatment for chronic disease within last 15 days. 6.Patient falling in grades III and IV of MIDAS score. 7.Patients with any infarction or seizure or any other cerebral condition associated with migraine.

Design outcomes

Primary

MeasureTime frame
Average Number of Migraine attack/monthTimepoint: baseline and 6 months

Secondary

MeasureTime frame
Disability due to migraineTimepoint: baseline, 3 months, 6 months;Migraine attack intensityTimepoint: Baseline and 6 months;Number of Pain killers takenTimepoint: baseline and 6 months

Countries

India

Contacts

Public ContactDivya Verma

Central Research Institute (Homoeopathy) Lucknow

vdivya1526@gmail.com9871332597

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026